Cargando…

Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer

D17DT consists of the GnRH decapeptide linked to diphtheria toxoid. The aim of this pilot study was to assess the tolerance of D17DT and the production of anti-GnRH antibodies from two doses, 30 and 100 μg, in patients with locally advanced prostate cancer. Twelve patients with histologically proven...

Descripción completa

Detalles Bibliográficos
Autores principales: Simms, M S, Scholfield, D P, Jacobs, E, Michaeli, D, Broome, P, Humphreys, J E, Bishop, M C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374644/
https://www.ncbi.nlm.nih.gov/pubmed/10945488
http://dx.doi.org/10.1054/bjoc.2000.1315
_version_ 1782154502331170816
author Simms, M S
Scholfield, D P
Jacobs, E
Michaeli, D
Broome, P
Humphreys, J E
Bishop, M C
author_facet Simms, M S
Scholfield, D P
Jacobs, E
Michaeli, D
Broome, P
Humphreys, J E
Bishop, M C
author_sort Simms, M S
collection PubMed
description D17DT consists of the GnRH decapeptide linked to diphtheria toxoid. The aim of this pilot study was to assess the tolerance of D17DT and the production of anti-GnRH antibodies from two doses, 30 and 100 μg, in patients with locally advanced prostate cancer. Twelve patients with histologically proven prostate cancer in whom hormonal therapy was indicated were recruited. Patients received either 30 or 100 μg given intramuscularly on three separate occasions over six weeks. Patients were followed up and blood was taken for estimation of serum testosterone, PSA and anti-GnRH antibody titre. Overall the drug was well tolerated. In 5 patients a significant reduction in serum testosterone and PSA was seen. Castrate levels of testosterone were achieved in 4 and maintained for up to 9 months. Patients with the highest antibody titre had the best response in terms of testosterone suppression. This study shows that it is possible to immunize a patient with prostate cancer against GnRH to induce castrate levels of testosterone. This state appears to be reversible. This novel form of immunotherapy may have advantages over conventional forms of hormonal therapy and further studies are warranted in order to try and increase the proportion of responders. © 2000 Cancer Research Campaign
format Text
id pubmed-2374644
institution National Center for Biotechnology Information
language English
publishDate 2000
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23746442009-09-10 Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer Simms, M S Scholfield, D P Jacobs, E Michaeli, D Broome, P Humphreys, J E Bishop, M C Br J Cancer Regular Article D17DT consists of the GnRH decapeptide linked to diphtheria toxoid. The aim of this pilot study was to assess the tolerance of D17DT and the production of anti-GnRH antibodies from two doses, 30 and 100 μg, in patients with locally advanced prostate cancer. Twelve patients with histologically proven prostate cancer in whom hormonal therapy was indicated were recruited. Patients received either 30 or 100 μg given intramuscularly on three separate occasions over six weeks. Patients were followed up and blood was taken for estimation of serum testosterone, PSA and anti-GnRH antibody titre. Overall the drug was well tolerated. In 5 patients a significant reduction in serum testosterone and PSA was seen. Castrate levels of testosterone were achieved in 4 and maintained for up to 9 months. Patients with the highest antibody titre had the best response in terms of testosterone suppression. This study shows that it is possible to immunize a patient with prostate cancer against GnRH to induce castrate levels of testosterone. This state appears to be reversible. This novel form of immunotherapy may have advantages over conventional forms of hormonal therapy and further studies are warranted in order to try and increase the proportion of responders. © 2000 Cancer Research Campaign Nature Publishing Group 2000-07 2000-07-24 /pmc/articles/PMC2374644/ /pubmed/10945488 http://dx.doi.org/10.1054/bjoc.2000.1315 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Simms, M S
Scholfield, D P
Jacobs, E
Michaeli, D
Broome, P
Humphreys, J E
Bishop, M C
Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer
title Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer
title_full Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer
title_fullStr Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer
title_full_unstemmed Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer
title_short Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer
title_sort anti-gnrh antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374644/
https://www.ncbi.nlm.nih.gov/pubmed/10945488
http://dx.doi.org/10.1054/bjoc.2000.1315
work_keys_str_mv AT simmsms antignrhantibodiescaninducecastratelevelsoftestosteroneinpatientswithadvancedprostatecancer
AT scholfielddp antignrhantibodiescaninducecastratelevelsoftestosteroneinpatientswithadvancedprostatecancer
AT jacobse antignrhantibodiescaninducecastratelevelsoftestosteroneinpatientswithadvancedprostatecancer
AT michaelid antignrhantibodiescaninducecastratelevelsoftestosteroneinpatientswithadvancedprostatecancer
AT broomep antignrhantibodiescaninducecastratelevelsoftestosteroneinpatientswithadvancedprostatecancer
AT humphreysje antignrhantibodiescaninducecastratelevelsoftestosteroneinpatientswithadvancedprostatecancer
AT bishopmc antignrhantibodiescaninducecastratelevelsoftestosteroneinpatientswithadvancedprostatecancer